Recovery Report: Broadview Networks Holdings Inc.'s Recovery Profile Sep 11

  • ID: 1922486
  • September 2011
  • Standard & Poors
1 of 3

Standard & Poor's Ratings Services has updated its recovery analysis on U.S. competitive local exchange carrier (CLEC) Broadview Networks Holdings Inc. in conjunction with the recent lowering of the company's corporate credit rating to 'CCC+' from 'B'. We lowered our issue-level rating on the company's secured notes to 'CCC' and the recovery rating remains unchanged at '5', following the review. Our simulated default scenario contemplates that better capitalized incumbent telephone companies accelerate their efforts to market and serve small-to-midsize business customers. The notes are guaranteed on a senior secured basis by each of the company's existing and future domestic restricted subsidiaries. The notes and the guarantees are secured by a lien on substantially all of the company's assets provided, however,...

Companies mentioned in this report are:
- Broadview Networks Holdings Inc.

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research Type: Full Analysis

Note: Product cover images may vary from those shown
2 of 3

- Broadview Networks Holdings Inc.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown


  • Quick Help: This Credit Rating Report will be emailed to you.


If you have a more general question about our products please try our



Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer, Inc.